Who is sponsoring NCT02783313?

NCT02783313 is sponsored by Sanquin Research & Blood Bank Divisions.

What condition does NCT02783313 study?

NCT02783313 studies Thrombocytopenia.

Is NCT02783313 still recruiting?

NCT02783313 is currently completed. Last updated 23 August 2018.

Last reviewed 2018-08-23 · How we verify

NCT02783313: PREPAReS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pathogen Reduction Evaluation & Predictive Analytical Rating Score

Completed NA Last updated 23 August 2018

What this trial tests

NA trial testing Pathogen reduced plasma-stored platelet concentrates in Thrombocytopenia in 567 participants. Completed in 30 June 2016.

Timeline

17 November 2010

Primary endpoint
30 April 2016

30 June 2016

Quick facts

Lead sponsor	Sanquin Research & Blood Bank Divisions
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	567
Start date	17 November 2010
Primary completion	30 April 2016
Estimated completion	30 June 2016
Sites	10 locations across Netherlands, Canada, Norway

Drugs / interventions tested

Pathogen reduced plasma-stored platelet concentrates
Plasma-stored platelet concentrates

Conditions studied

Thrombocytopenia — all drugs for Thrombocytopenia →

Sponsor

Sanquin Research & Blood Bank Divisions — full company profile →

Who can join

18 and older, any sex, with Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to determine if pooled buffy coat-derived pathogen reduced plasma-stored platelet concentrates are non-inferior compared to plasma-stored platelet concentrates in terms of WHO bleeding complications in hemato-oncological patients with thrombocytopenia.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial.
van der Meer PF, Ypma PF, van Geloven N, van Hilten JA, et al · · 2018 · cited 60× · PMID 29773572 · DOI 10.1182/blood-2018-02-831289
The association between haemorrhage and markers of endothelial insufficiency and inflammation in patients with hypoproliferative thrombocytopenia: a cohort study.
Ypma PF, van Geloven N, Kerkhoffs JLH, Te Boekhorst P, et al · · 2020 · cited 9× · PMID 31730713 · DOI 10.1111/bjh.16291
Impact of platelet transfusions on plasma proteomes in controlled endotoxemia and in hemato-oncological patients.
Smit ER, Viegen I, van der Meer PF, van Wonderen SF, et al · · 2025 · cited 2× · PMID 40903865 · DOI 10.1111/trf.18397
Plasma proteomes of acute myeloid leukemia patients treated with transfusions reveal signatures of inflammation and hemostatic dysregulation.
Smit ER, Muñoz Sandoval D, Kreft IC, van der Meer PF, et al · · 2024 · cited 2× · PMID 40078206 · DOI 10.1186/s41231-024-00189-5
Hemostatic and platelet proteins are associated with bleeding grade and time to major bleed in hemato-oncological patients.
Muñoz Sandoval D, Smit ER, Rojas-Rodriguez F, van der Meer PF, et al · · 2026 · PMID 41971716 · DOI 10.1016/j.bvth.2026.100144
EHA2024 Hybrid Congress
· 2024

Verify or expand the search:

Other recruiting trials for Thrombocytopenia

Currently open trials in the same condition.

NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
NCT07442513 — Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT · Phase 3 · recruiting
NCT07257809 — Herombopag Treated T-DM1 Induced Platelet Reduction · Phase 2 · recruiting
NCT06676904 — Neonatal Platelet Transfusion Threshold Trial · NA · recruiting
NCT06886516 — Apixaban in Thrombocytopenia · EARLY_PHASE1 · recruiting

Other Sanquin Research & Blood Bank Divisions trials

Trials by the same sponsor.

NCT04024202 — Data Registry of Auto Immune Hemolytic Anemia · unknown
NCT03539159 — Assessment of the Mu-Drop System for Serum Eye Drops · NA · unknown
NCT03288012 — Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics · unknown
NCT03085290 — Allogeneic Versus Autologous Serum Eye Drops · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02783313 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanquin Research & Blood Bank Divisions
Last refreshed: 23 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02783313.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing